Previous 10 | Next 10 |
- Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined commercial manufacturing process - - Ended quarter with $1.41 billi...
Shares of CRISPR Therapeutics (NASDAQ: CRSP) have gained 52% in 2019, but the stock is still 40% below the record high price it reached in 2018. If you've been holding onto shares of the gene-editing pioneer since their heyday last May, now is not the time to let go. While reporting third-q...
Company Overview Allogene Therapeutics ( ALLO ) is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (“AlloCAR T”) therapies for cancer. Allogene believes that the next revolution in cancer treatment is the development of AlloCAR T therapie...
The recent approval of various gene therapies, for example, Luxturna and Zolgesma and high premium acquisitions of gene therapy companies have shifted the investor focus to this rapidly growing biotechnology field. In this series of review articles, I will review the gene therapy and gene edit...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020. “On behalf of bluebird, we are grateful for all that Jeff has accomplished over the past eight years in a va...
The European Medicines Agency (EMA) has signed off on the commercial drug product specifications for bluebird bio's ( BLUE -2.3% ) Zynteglo (autologous CD34+ cells encoding β A-T87Q -globin gene), a one-time gene therapy for patients at least 12 years with transfusion-dependent ...
First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β 0 /β 0 genotype now available to be manufactured in the European Union bluebird bio, Inc. (Nasdaq: BLUE) announced today that the European Medicines Age...
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
CRISPR Therapeutics ( CRSP ) has been on my watchlist for a couple of years but the stars never aligned for me to pull the trigger on a buy. Due to some recent updates, I am moving CRSP up to the top of my year-end shopping list and will be stalking an entry point in the coming weeks or months...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...